Pharming Completes Enrollment in Pediatric Clinical Trial of leniolisib
Pharming Group has recently completed patient enrollment in its Phase III clinical trial (NCT05438407) evaluating the investigational drug leniolisib.
APDS | 09/04/2024 | By Aishwarya | 145
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy